共 50 条
- [31] Anti-CTLA-4 and anti-PD-1 immunotherapies repress tumor progression in preclinical breast and colon model with independent regulatory T cells responseTRANSLATIONAL ONCOLOGY, 2022, 20Rupp, TristanGenest, LaurieBabin, DavidLegrand, ChristopheHunault, MarionFroget, GuillaumeCastagne, Vincent
- [32] Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV+ oral cancerJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01)Dorta-Estremera, StephanieHegde, Venkatesh L.Slay, Ravaen B.Sun, RachelYanamandra, Ananta, VNicholas, CourtneyNookala, SitaSierra, GloriaCurran, Michael A.Sastry, K. Jagannadha
- [33] Prognostic factors for survival in patients with metastatic skin melanoma, receiving first- line treatment with anti-PD-1 or anti-PD-1 and anti-CTLA-4 immunotherapy regimen at the Instituto Nacional de Cancerolog?a (Bogot?, Colombia)REVISTA COLOMBIANA DE CANCEROLOGIA, 2023, 27 (01): : 91 - 102Marcela Zuluaga-Liberato, AndreaEduardo Bonilla-Gonzalez, CarlosContreras-Mejia, FernandoAlexander Carreno-Duenas, Jose
- [34] Efficacy comparison between anti-PD-1 antibody monotherapy and anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy for advanced acral melanoma: A retrospective, multicenter study of 254 Japanese patientsEUROPEAN JOURNAL OF CANCER, 2022, 176 : 78 - 87Nakamura, YasuhiroNamikawa, KenjiroKiniwa, YukikoKato, HiroshiYamasaki, OsamuYoshikawa, ShusukeMaekawa, TakeoMatsushita, ShigetoTakenouchi, TatsuyaInozume, TakashiNakai, YasuoFukushima, SatoshiSaito, ShintaroOtsuka, AtsushiFujimoto, NorikiIsei, TaikiBaba, NatsukiMatsuya, TaisukeTanaka, RyoKaneko, TakahideOnishi, MasazumiKuwatsuka, YutakaNagase, KotaroOnuma, TakehiroNomura, MotooUmeda, YoshiyasuYamazaki, Naoya
- [35] Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cellsCANCER CELL, 2024, 42 (09)Wang, KevinCoutifaris, PaulinaBrocks, DavidWang, GuanningAzar, TarekSolis, SabrinaNandi, AjeyaAnderson, ShaneakaHan, NicholasManne, SasikanthKiner, EvgenySachar, ChiragLucas, MinkeGeorge, SangeethYan, Patrick K.Kier, Melanie W.Laughlin, Amy I.Kothari, ShawnGiles, JosephineMathew, DivijGhinnagow, ReemAlanio, CecileFlowers, AhronXu, WeiTenney, Daniel J.Xu, XiaoweiAmaravadi, Ravi K.Karakousis, Giorgos C.Schuchter, Lynn M.Buggert, MarcusOldridge, DerekMinn, Andy J.Blank, ChristianWeber, Jeffrey S.Mitchell, Tara C.Farwell, Michael D.Herati, Ramin S.Huang, Alexander C.
- [36] Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study)ESMO OPEN, 2021, 6 (06)Nakamura, Y.Namikawa, K.Yoshikawa, S.Kiniwa, Y.Maekawa, T.Yamasaki, O.Isei, T.Matsushita, S.Nomura, M.Nakai, Y.Fukushima, S.Saito, S.Takenouchi, T.Tanaka, R.Kato, H.Otsuka, A.Matsuya, T.Baba, N.Nagase, K.Inozume, T.Fujimoto, N.Kuwatsuka, Y.Onishi, M.Kaneko, T.Onuma, T.Umeda, Y.Ogata, D.Takahashi, A.Otsuka, M.Teramoto, Y.Yamazaki, N.
- [37] Comparing the clinical efficacies of anti-PD-1 antibody monotherapy and anti-PD-1 and anti-CTLA-4 combination therapy as first-line immunotherapy in Japanese advanced acral melanoma: A retrospective, multicenter study (JAMP-neo study).JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Nakamura, YasuhiroKiniwa, YukikoKato, HiroshiYamasaki, OsamuMaekawa, TakeoMatsushita, ShigetoTakenouchi, TatsuyaInozume, TakashiNakai, YasuoFukushima, SatoshiSaito, ShintaroOtsuka, AtsushiFujimoto, NorikiIsei, TaikiBaba, NatsukiMatsuya, TaisukeTanaka, RyoKaneko, TakahideOnishi, MasazumiYoshikawa, Shusuke
- [38] Ex vivo modulation of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes (vol 14, 1180997, 2023)FRONTIERS IN IMMUNOLOGY, 2024, 15Hulen, Thomas MorganFriese, ChristinaKristensen, Nikolaj PaghGranhoj, Joachim StoltenborgBorch, Troels HolzPeeters, Marlies J. W.Donia, MarcoAndersen, Mads HaldHadrup, Sine RekerSvane, Inge MarieMet, Ozcan
- [39] FC-ENHANCED ANTI-CTLA-4 IMMUNE CHECKPOINT BLOCKADE AND ITS COMBINATION WITH ANTI-PD-1 WITH CONCOMITANT DOXORUBICIN AND ULTRASOUNDMEDIATED BBB OPENING: A NOVEL IMMUNOTHERAPY FOR GLIOBLASTOMA.NEURO-ONCOLOGY, 2023, 25Kim, Kwang-SooHabashy, KarlGould, AndrewNajem, HindaZhao, JunfeiAmidei, ChristinaSaganty, RuthArrieta, VictorDmello, CrismitaChen, LiZhang, DanielCastro, BrandynBillingham, LeahLevey, DanielMorin, BenjaminMuzzio, MiguelCanney, MichaelMcCortney, KatyHorbinski, CraigZhang, PengMiska, JasonRabadan, RaulHeimberger, AmyStupp, RogerChand, DhanLee-Chang, CatalinaSonabend, Adam
- [40] A PHASE II BASKET TRIAL OF DUAL ANTI-CTLA-4 AND ANTI-PD-1 BLOCKADE IN RARE TUMORS (DART) SWOG S1609: THE THYROID TUMOR COHORTJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A161 - A161Chae, Young KwangOthus, MeganPatel, SandipFenton, SarahWang, DingRodriguez, CristinaOnitilo, AdedayoMattour, AhmadRybkin, IgorHayward, JourdainMcLeod, ChristineChen, HelenSharon, EladMayerson, EdwardRyan, ChristopherPlets, MelissaBlanke, CharlesKurzrock, Razelle